Piramal Pharma's FY2026 Annual Report showcases global scale, innovation
Published on: July 7, 2026, 6:48 p.m. | Source: The Tribune
Mumbai (Maharashtra) [India], July 7: Piramal Pharma Limited (PPL) (NSE: PPLPHARMA) (BSE: 543635), a leading global pharmaceutical, health and wellness company, released its Annual Report for FY2026, highlighting a year of strengthening its global platform, investing in differentiated capabilities, advancing sustainability, and delivering quality across operations. The report reflects Piramal Pharma's continued commitment to improving patient outcomes through science-led innovation, operational excellence and quality, while building a resilient global platform that serves customers across regulated markets worldwide.
